Eternity Insights can provide a deep dive research report highlighting the market and competitive intelligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Companion Diagnostics market. The report considers 2019-2022 historic period, 2023 as base year, and 2024-2034 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition.
Companion Diagnostics market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
The Companion Diagnostics market is estimated to expand at a considerable growth rate during the forecast period owing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of Companion Diagnostics products across developed and developing countries of the world.
Limited awareness about diseases, high product costs, low economic conditions, and lack of favorable insurance systems restrict the adoption of Companion Diagnostics products across developing regions of the globe. However, launching new low-cost products and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Companion Diagnostics market.
To learn more about this report
Increasing research and development spending on Companion Diagnostics development has been the leading industry trend of Companion Diagnostics market
The leading players in the market are focused on developing cost-effective, high-quality products to tap the huge unaddressed opportunities in developing regions. This can be witnessed by the increasing spending on research and development and the growing number of new product approvals.
To learn more about this report
| Report Attributes | Details |
| The market size value in 2023 | USD XX.XX Million |
| CAGR (2024 - 2034) | XX.XX % |
| The Revenue forecast in 2034 | USD XX.XX Million |
| Base year for estimation | 2023 |
| Historical data | 2019-2034 |
| Forecast period | 2024-2034 |
| Quantitative units |
|
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook | Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next Generation Sequencing (NGS) |
| By Application Outlook | Hospitals, Pharmaceutical Companies, Laboratories, Other |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope | U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled | Roche Holdings, Abbott Laboratories, Thermo Fisher Scientific, Agilent Technologies, Life Technologies, GE Healthcare, Agendia, Qiagen, Genomic Health, Myriad Genetics, Advanced Cell Diagnostics, Danaher, Applied Proteomics |
| Customization Available | Yes, the report can be tailored to meet your specific requirements. |
1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Information Procurement
1.2.1 Purchased Database
1.2.2 Eternity’s Internal Database
1.2.3 Secondary sources & third-party perspectives
1.2.4 Primary Research
1.3 Information analysis
1.4 Market formulation & data visualization
1.5 Data validation & publishing
2 Executive Summary
3 Companion Diagnostics Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.2 Market Restraints
3.1.3 Market Challenge Analysis
3.1.4 Market Opportunities
3.1.5 Micro & Macro Indicator
3.2 Impact of COVID-19 Pandemic on Global Companion Diagnostics Market
3.2.1 Overview of Changing Landscape
3.2.2 Pre-covid & Post-Covid Market Analysis
3.3 Market Attractiveness Analysis
3.4 Regulatory Scenario
3.5 Industry Trend Analysis- Historic and Future Trend Assessment
3.6 Merger & Acquisition
3.7 New System Launch/Approvals
3.8 Market Analysis Tools
3.8.1 Porter’s Five Forces
3.8.2 PEST Analysis
3.8.3 Value Chain Analysis
3.9 Key Company Ranking Analysis, 2020
4 Global Companion Diagnostics Market Analysis and Forecast, By Type
4.1 Overview & Definition
4.2 Key Trends
4.3 Global Companion Diagnostics Market Value (US$ Mn) Forecast, by Type (2019 – 2028)
4.2.1 Polymerase Chain Reaction (PCR)
4.2.2 Immunohistochemistry (IHC)
4.2.3 In Situ Hybridization (ISH)
4.2.4 Next Generation Sequencing (NGS)
4.4 Type Comparison Matrix
4.5 Global Companion Diagnostics Market Attractiveness, By Type
5 Global Companion Diagnostics Market Analysis and Forecast, By Application
5.1 Overview & Definition
5.2 Key Trends
5.3 Global Companion Diagnostics Market Value (US$ Mn) Forecast, by Application (2019 – 2028)
5.3.1 Hospitals
5.3.2 Pharmaceutical Companies
5.3.3 Laboratories
5.3.4 Other
5.4 Application Comparison Matrix
5.5 Global Companion Diagnostics Market Attractiveness, by Application
6 Global Companion Diagnostics Market Analysis and Forecast, By Region
6.1 Overview & Definition
6.2 Key Trends
6.3 Global Companion Diagnostics Market Value (US$ Mn) Forecast, by Region (2019 – 2028)
6.4 North America
6.5 Europe
6.6 Asia Pacific
6.7 Latin America
6.8 Middle East & Africa
7 Global Companion Diagnostics Market Attractiveness, by Region
8 North America Companion Diagnostics Market Analysis and Forecast
8.1 Key Findings
8.2 North America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
8.2.1 Polymerase Chain Reaction (PCR)
8.2.2 Immunohistochemistry (IHC)
8.2.3 In Situ Hybridization (ISH)
8.2.4 Next Generation Sequencing (NGS)
8.3 North America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
8.3.1 Hospitals
8.3.2 Pharmaceutical Companies
8.3.3 Laboratories
8.3.4 Other
8.4 North America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
8.4.1 U.S.
8.4.2 Canada
8.4.3 Rest of North America
8.5 North America Companion Diagnostics Market Attractiveness Analysis
8.5.1 By Type
8.5.2 By Application
8.5.3 By Country
9 Europe Companion Diagnostics Market Analysis and Forecast
9.1 Key Findings
9.2 Europe Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
9.2.1 Polymerase Chain Reaction (PCR)
9.2.2 Immunohistochemistry (IHC)
9.2.3 In Situ Hybridization (ISH)
9.2.4 Next Generation Sequencing (NGS)
9.3 Europe Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
9.3.1 Hospitals
9.3.2 Pharmaceutical Companies
9.3.3 Laboratories
9.3.4 Other
9.4 Europe Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
9.4.1 U.K.
9.4.2 Germany
9.4.3 France
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Europe Companion Diagnostics Market Attractiveness Analysis
9.5.1 By Type
9.5.2 By Application
9.5.3 By Country
10 Asia Pacific Companion Diagnostics Market Analysis and Forecast
10.1 Key Findings
10.2 Asia Pacific Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
10.2.1 Polymerase Chain Reaction (PCR)
10.2.2 Immunohistochemistry (IHC)
10.2.3 In Situ Hybridization (ISH)
10.2.4 Next Generation Sequencing (NGS)
10.3 Asia Pacific Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
10.3.1 Hospitals
10.3.2 Pharmaceutical Companies
10.3.3 Laboratories
10.3.4 Other
10.4 Asia Pacific Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Asia Pacific Companion Diagnostics Market Attractiveness Analysis
10.5.1 By Type
10.5.2 By Application
10.5.3 By Country
11 Latin America Companion Diagnostics Market Analysis and Forecast
11.1 Key Findings
11.2 Latin America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
11.2.1 Polymerase Chain Reaction (PCR)
11.2.2 Immunohistochemistry (IHC)
11.2.3 In Situ Hybridization (ISH)
11.2.4 Next Generation Sequencing (NGS)
11.3 Latin America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
11.3.1 Hospitals
11.3.2 Pharmaceutical Companies
11.3.3 Laboratories
11.3.4 Other
11.4 Latin America Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
11.4.1 Brazil
11.4.2 Rest of Latin America China
11.5 Latin America Companion Diagnostics Market Attractiveness Analysis
11.5.1 By Type
11.5.2 By Application
11.5.3 By Country
12 Middle East & Africa (MEA) Companion Diagnostics Market Analysis and Forecast
12.1 Key Findings
12.2 Middle East & Africa (MEA) Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Product Type (2019-2028)
12.2.1 Polymerase Chain Reaction (PCR)
12.2.2 Immunohistochemistry (IHC)
12.2.3 In Situ Hybridization (ISH)
12.2.4 Next Generation Sequencing (NGS)
12.3 Middle East & Africa (MEA) Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
12.3.1 Hospitals
12.3.2 Pharmaceutical Companies
12.3.3 Laboratories
12.3.4 Other
12.4 Middle East & Africa (MEA) Companion Diagnostics Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
12.4.1 GCC Countries
12.4.2 South Africa
12.4.3 Rest of MEA
12.5 Middle East & Africa (MEA) Companion Diagnostics Market Attractiveness Analysis
12.5.1 By Type
12.5.2 By Application
12.5.3 By Country
13 Competitive Landscape
13.1 Market Players – Competition Matrix
13.2 Market Share Analysis by Key Players, 2020 (%)
13.3 Company Profiles
13.3.1 Roche Holdings
13.3.1.1 Company Overview
13.3.1.2 Company Snapshot
13.3.1.3 Financial Overview
13.3.1.4 Product Portfolio
13.3.1.5 Key Developments/Strategies
13.3.2 Abbott Laboratories
13.3.3 Thermo Fisher Scientific
13.3.4 Agilent Technologies
13.3.5 Life Technologies
13.3.6 GE Healthcare
13.3.7 Agendia
13.3.8 Qiagen
13.3.9 Genomic Health
13.3.10 Myriad Genetics
13.3.11 Advanced Cell Diagnostics
13.3.12 Danaher
13.3.13 Applied Proteomics
14 Key Takeaways
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
A faster and efficient way to cater to the needs with continuous iteration
Focus on Data Accuracy & Reliability
75+ Clients in Fortune 500
All your transactions are secured end-to-end, ensuring a satisfactory purchase
Ensure the best and affordable pricing
